Patents Assigned to F. Hoffmann-La Roche AG
  • Patent number: 10799523
    Abstract: The present invention relates to oligomer compounds (oligomers), which target Tau mRNA in a cell, leading to reduced expression of Tau protein. Reduction of Tau protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: October 13, 2020
    Assignee: F. HOFFMANN-LA ROCHE AG
    Inventors: Richard E. Olson, Angela M. Cacace, Peter Hagedorn, Anja Mølhart Høg, Dong Li, Jeffrey M. Brown, Marianne Lerbech Jensen, Niels Fisker Nielsen, Stephen E. Mercer
  • Patent number: 10787505
    Abstract: The present invention relates to an oligopeptide and conjugates thereof. The present invention also relates to the use of these oligopeptide conjugates for treating or diagnosing disorders mediated by amyloid ? deposits. Finally, the present invention also relates to a coupling method for obtaining oligopeptide coupled with a substance of interest (functional conjugates).
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: September 29, 2020
    Assignees: F. HOFFMANN-LA ROCHE AG, INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
    Inventors: Pierre Lafaye, Sylvie Bay, Benoit Delatour, Marc Dhenain, Charles Duyckaerts, Tengfei Li, Matthias Vandesquille, Christian Czech, Fiona Grueninger
  • Patent number: 10782300
    Abstract: The present invention discloses a method for determining the efficacy of GPC3-targeting drug therapy for cancer in a patient before the start of GPC3-targeting drug therapy or a patient or determining the continuation of GPC3-targeting drug therapy for a patient, including monitoring a concentration of free GPC3 in a biological sample isolated from the patient before the start of GPC3-targeting drug therapy and/or the patient treated with the GPC3-targeting drug therapy, wherein when the concentration of free GPC3 is a predetermined value, the efficacy of the GPC3-targeting drug therapy is determined or the continuation of the GPC3-targeting drug therapy is determined. The present invention also discloses a GPC3-targeting drug or a preparation which is to be further administered to a patient for which the efficacy of the GPC3-targeting drug therapy has been determined or the continuation of the GPC3-targeting drug therapy has been determined.
    Type: Grant
    Filed: December 24, 2013
    Date of Patent: September 22, 2020
    Assignees: CHUGAI SEIYAKU KABUSHIKI KAISHA, F. Hoffmann-La Roche AG
    Inventors: Toshihiko Ohtomo, Ya-Chi Chen, Jun Amano, Mikiko Nakamura
  • Publication number: 20200253963
    Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
    Type: Application
    Filed: March 23, 2020
    Publication date: August 13, 2020
    Applicants: GENENTECH, INC., F. HOFFMANN-LA ROCHE AG
    Inventors: Deepak Sampath, Christian Klein, Wayne John Fairbrother
  • Patent number: 10654940
    Abstract: Methods of treating joint damage in a subject eligible for treatment are provided involving administering an antagonist that binds to a B-cell surface marker, such as CD20 antibody, to the subject in an amount effective to slow progression of the joint damage as measured by radiography. Further provided are articles of manufacture useful for such methods.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: May 19, 2020
    Assignees: Genentech, Inc., F. Hoffmann-La Roche AG, Biogen Inc.
    Inventors: Mark Totoritis, Timothy Mark Shaw, Sunil Agarwal, David Yocum, Ariella Kelman
  • Patent number: 10538582
    Abstract: The present invention relates to variable domains of a camelid heavy-chain antibodies directed against a phosphorylated tau protein and conjugates thereof. The present invention also relates to the use of these domains or conjugates for treating or diagnosing disorders mediated by neurofibrillary tangles, neuropil threads or dystrophic neurites, such as tauopathies.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: January 21, 2020
    Assignees: F. HOFFMANN-LA ROCHE AG, INSTITUT PASTEUR, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Pierre Lafaye, Sylvie Bay, Benoit Delatour, Marc Dhenain, Charles Duyckaerts, Tengfei Li, Matthias Vandesquille, Christian Czech, Fiona Grueninger
  • Patent number: 10479780
    Abstract: An objective of the present invention is to provide low-molecular-weight compounds that can inhibit Src family kinases. The present invention relates to compounds represented by general formula (I) or pharmacologically acceptable salts thereof. In the formula, Ar1 is optionally substituted C6-10 arylene or 5- to 10-membered heteroarylene, and Ar2 is optionally substituted C6-10 aryl or 5- to 10-membered heteroaryl. R1 and R2 are defined as described in the specification.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: November 19, 2019
    Assignees: Chugai Seiyaku Kabushiki Kaisha, F. Hoffmann-La Roche AG
    Inventors: Hirosato Ebiike, Toshihiro Aoki, Takashi Chiba, Masami Kochi, Kimitaka Nakama, Satoshi Niizuma, Hiroki Nishii, Jun Ohwada, Hiroyuki Shimamura, Aiko Suge, Yoshito Nakanishi, Natsuki Kobayashi
  • Patent number: 10457648
    Abstract: The present disclosure relates to processes for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds, and more particularly relates to processes for preparing (R)-4-(5-methyl-7-oxo-6,7-dihydro-5H-cyclopenta[d] pyrimidin-4-yl)piperazine and N-protected derivatives thereof, which may be used as an intermediate in the synthesis of Ipatasertib (i.e., (S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)-propan-1-one). The present disclosure additionally relates to various compounds that are intermediates employed in these processes.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: October 29, 2019
    Assignees: GENENTECH INC., F. HOFFMANN-LA ROCHE AG
    Inventors: Francis Gosselin, Chong Han, Hans Iding, Reinhard Reents, Scott Savage, Beat Wirz
  • Patent number: 10450379
    Abstract: Methods of treating joint damage in a subject eligible for treatment are provided involving administering an antagonist that binds to a B-cell surface marker, such as CD20 antibody, to the subject in an amount effective to slow progression of the joint damage as measured by radiography. Further provided are articles of manufacture useful for such methods.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: October 22, 2019
    Assignees: Genetech, Inc., F. Hoffmann-La Roche AG, Biogen Inc.
    Inventors: Mark Totoritis, Timothy Mark Shaw, Sunil Agarwal, David Yocum, Ariella Kelman
  • Patent number: 10417937
    Abstract: The training device for medicine injection devices comprises a plunger slidably arranged in the cavity of a body. The plunger comprises a compressible element arranged at a distal end of the plunger and adapted to provide a resistance between compressible element and inner wall if the cavity of the body when the plunger is moved in the cavity towards the distal end of the body. The resistance corresponds to an injection resistance of a medicine injected into a patient. The invention also comprises a reset device for resetting the training device from a used status to a condition for reuse.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: September 17, 2019
    Assignee: F. Hoffmann-La Roche AG
    Inventors: Maxime Gaillot, Mark Anthony Chipperfield, Mark Teucher, Paul Hayton
  • Publication number: 20190194352
    Abstract: An objective of the present invention is to provide an effective pharmaceutical composition or a dosage regimen for preventing and/or treating bleeding, a disease accompanying bleeding, or a disease caused by bleeding. The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes (a) blood coagulation factor IX and/or activated blood coagulation factor IX and (b) blood coagulation factor X and/or activated blood coagulation factor X according to a given dosage regimen, bleeding, a disease accompanying bleeding, or a disease caused by bleeding can be prevented and/or treated more effectively.
    Type: Application
    Filed: September 5, 2017
    Publication date: June 27, 2019
    Applicants: Chugai Seiyaku Kabushiki Kaisha, F. Hoffmann-La Roche AG
    Inventors: Koichiro Yoneyama, Christophe Schmitt
  • Publication number: 20190106421
    Abstract: The present invention relates to a process for producing crystalline and amorphous forms of a diazabicyclooctane derivative represented by Compound (I) and methods for producing the same.
    Type: Application
    Filed: September 25, 2018
    Publication date: April 11, 2019
    Applicant: F. Hoffmann-La Roche AG
    Inventors: Michael KAMMERER, Frédéric RAN
  • Publication number: 20180362509
    Abstract: An objective of the present invention is to provide low-molecular-weight compounds that can inhibit Src family kinases. The present invention relates to compounds represented by general formula (I) or pharmacologically acceptable salts thereof. In the formula, Ar1 is optionally substituted C6-10 arylene or 5- to 10-membered heteroarylene, and Ar2 is optionally substituted C6-10 aryl or 5- to 10-membered heteroaryl. R1 and R2 are defined as described in the specification.
    Type: Application
    Filed: June 17, 2016
    Publication date: December 20, 2018
    Applicants: Chugai Seiyaku Kabushiki Kaisha, F. Hoffmann-La Roche AG
    Inventors: Hirosato Ebiike, Toshihiro Aoki, Takashi Chiba, Masami Kochi, Kimitaka Nakama, Satoshi Niizuma, Hiroki Nishii, Jun Ohwada, Hiroyuki Shimamura, Aiko Suge, Yoshito Nakanishi, Natsuki Kobayashi
  • Publication number: 20180296470
    Abstract: Fixed dose HER2 antibody formulations for subcutaneous administration are provided along with their use in the treatment of cancer. The formulations include fixed dose subcutaneous formulations of pertuzumab and subcutaneous co-formulations of pertuzumab and trastuzumab, and their use in the treatment of cancer.
    Type: Application
    Filed: January 16, 2018
    Publication date: October 18, 2018
    Applicants: Genentech, Inc., F. Hoffmann-La Roche AG
    Inventors: Jennifer Eng-Wong, Whitney Kirschbrown, Tarik Khan, Jasper Lin, Sreedhara Alavattam, Amit Garg, Sarah Heeson, Tanja Badovinac-Crnjevic, Christine Wurth
  • Patent number: 10087245
    Abstract: The present invention relates to variable domains of a camelid heavy-chain antibodies directed against a phosphorylated tau protein and conjugates thereof. The present invention also relates to the use of these domains or conjugates for treating or diagnosing disorders mediated by neurofibrillary tangles, neuropil threads or dystrophic neurites, such as tauopathies.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: October 2, 2018
    Assignees: F. HOFFMANN-LA ROCHE AG, INSTITUT PASTEUR, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Pierre Lafaye, Sylvie Bay, Benoit Delatour, Marc Dhenain, Charles Duyckaerts, Tengfei Li, Matthias Vandesquille, Christian Czech, Fiona Grueninger
  • Patent number: 10087237
    Abstract: Herein is reported a method for producing an antibody preparation comprising the steps of a) applying a buffered solution comprising different isoforms of an antibody to a cation exchange chromatography material, b) applying a first solution with a first conductivity to the cation exchange chromatography material, whereby the antibody isoforms remain bound to the cation exchange chromatography material, and c) applying a second solution with a second conductivity to the cation exchange chromatography material and thereby obtaining the antibody preparation, whereby the conductivity of the second solution exceeds the conductivity of the first solution by not more than 10%.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: October 2, 2018
    Assignee: F. HOFFMANN-LA ROCHE AG
    Inventors: Roberto Falkenstein, Klaus Schwendner, Bernhard Spensberger
  • Publication number: 20180250397
    Abstract: Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.
    Type: Application
    Filed: February 28, 2018
    Publication date: September 6, 2018
    Applicants: Genentech, Inc., F. Hoffmann-La Roche AG
    Inventors: Mark C. BENYUNES, Graham Alexander ROSS
  • Patent number: 9943519
    Abstract: Compounds of Formulae Ia, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: April 17, 2018
    Assignees: Genentech, Inc., F. Hoffmann-La Roche AG
    Inventors: Adrian Folkes, Stephen Shuttleworth, Irina Chuckowree, Sally Oxenford, Nan Chi Wan, Georgette Castanedo, Richard Goldsmith, Janet Gunzer-Toste, Tim Heffron, Simon Mathieu, Alan Olivero, Daniel P. Sutherlin, Bing-Yan Zhu
  • Patent number: D856168
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: August 13, 2019
    Assignee: F. Hoffmann-La Roche AG
    Inventors: Marcella Makowski, Monica Tavanti, Chris Muenzer, Laura Isabel Duran-Noy, Geraint Davies, Roberta Leah, Lee Wood
  • Patent number: D903109
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: November 24, 2020
    Assignee: F. Hoffmann-La Roche AG
    Inventor: Florian Wildenhahn